Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
Applied Therapeutics (Nasdaq: APLT), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 UBS Global Healthcare Conference. The presentation is scheduled for Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.
The company will provide a live webcast of the event through their website's Investor Relations section at www.appliedtherapeutics.com. Interested parties can access the presentation recording for 90 days following the event on the company's website.
Applied Therapeutics (Nasdaq: APLT), una compagnia biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al 2024 UBS Global Healthcare Conference. La presentazione è programmata per martedì 12 novembre 2024, alle 7:15 a.m. PT a Rancho Palos Verdes, California.
L'azienda offrirà una diretta streaming dell'evento attraverso la sezione Relazioni con gli Investitori del loro sito web all'indirizzo www.appliedtherapeutics.com. Le parti interessate potranno accedere alla registrazione della presentazione per 90 giorni dopo l'evento sul sito dell'azienda.
Applied Therapeutics (Nasdaq: APLT), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en la 2024 UBS Global Healthcare Conference. La presentación está programada para el martes 12 de noviembre de 2024, a las 7:15 a.m. PT en Rancho Palos Verdes, California.
La compañía ofrecerá una transmisión en vivo del evento a través de la sección de Relaciones con Inversores de su sitio web en www.appliedtherapeutics.com. Las partes interesadas podrán acceder a la grabación de la presentación durante 90 días después del evento en el sitio web de la empresa.
Applied Therapeutics (Nasdaq: APLT), 임상 단계의 생명공학 회사가 2024 UBS 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 발표는 2024년 11월 12일 화요일 오전 7시 15분(PT) 캘리포니아 랜초팔로스베르데스에서 예정되어 있습니다.
회사는 www.appliedtherapeutics.com에서 투자자 관계 섹션을 통해 이벤트의 실시간 웹캐스트를 제공합니다. 관심 있는 사람들은 이벤트 이후 90일 동안 회사 웹사이트에서 발표 기록을 접근할 수 있습니다.
Applied Therapeutics (Nasdaq: APLT), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 2024 UBS Global Healthcare Conference. La présentation est prévue pour le mardi 12 novembre 2024, à 7h15 PT à Rancho Palos Verdes, Californie.
L'entreprise fournira une diffusion en direct de l'événement via la section Relations Investisseurs de son site web à l'adresse www.appliedtherapeutics.com. Les parties intéressées pourront accéder à l'enregistrement de la présentation pendant 90 jours après l'événement sur le site de l'entreprise.
Applied Therapeutics (Nasdaq: APLT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 2024 UBS Global Healthcare Conference angekündigt. Die Präsentation ist für Dienstag, den 12. November 2024, um 7:15 Uhr PT in Rancho Palos Verdes, Kalifornien, angesetzt.
Das Unternehmen wird eine Live-Übertragung der Veranstaltung über den Bereich Investor Relations auf ihrer Website unter www.appliedtherapeutics.com anbieten. Interessierte Parteien können die Aufzeichnung der Präsentation für 90 Tage nach der Veranstaltung auf der Website des Unternehmens abrufen.
- None.
- None.
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.
A live webcast for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay of the webcast will be archived on the Company’s website for 90 days following the event.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.
Contacts
Investors:
Julie Seidel/Andrew Vulis
646-970-0543
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
FAQ
When is Applied Therapeutics (APLT) presenting at the 2024 UBS Global Healthcare Conference?
How can I watch Applied Therapeutics' (APLT) presentation at the UBS Healthcare Conference?
How long will Applied Therapeutics' (APLT) UBS Conference presentation be available for replay?
Where is Applied Therapeutics (APLT) presenting at the 2024 UBS Global Healthcare Conference?
